• FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  June 9, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for EBGLYSS (lebriki···【Read More】

  Update: 10 Jun,2026Source: BigbearViews: 81

• Autobahn accelerates toward pivotal clinical trials: Thyroid hormone mimetic relieves bipolar depression in phase 2 trial

  Elunetirom is a small molecule drug taken orally once daily. After six weeks of treatment, patients' depression severity decreased by an average o···【Read More】

  Update: 05 Jun,2026Source: BigbearViews: 102

• FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections

  May 30, 2026 – Wockhardt announced that the U.S. Food and Drug Administration (FDA) has approved Zaynich (cefepime and zidebactam), a novel intravenou···【Read More】

  Update: 03 Jun,2026Source: BigbearViews: 103

• EMA Recommends Extending Indications for Decitabine /Cedazuridine

  On 23 April 2026, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommendi···【Read More】

  Update: 01 Jun,2026Source: BigbearViews: 105

• FDA Approves Use of Linzess (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

  May 27, 2026 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for peop···【Read More】

  Update: 28 May,2026Source: BigbearViews: 108

• FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Decnupaz (pivekimab sun···【Read More】

  Update: 28 May,2026Source: BigbearViews: 112

• FDA approves the first all-oral combination regimen for patients with acute myeloid leukemia who cannot tolerate intensive induction chemotherapy

  On May 13, 2026, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved decit···【Read More】

  Update: 27 May,2026Source: BigbearViews: 110

• FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) Treatment for Chronic Hepatitis Delta Virus (HDV)

  FOSTER CITY, Calif.--(BUSINESS WIRE) May 22, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (···【Read More】

  Update: 25 May,2026Source: BigbearViews: 127

• FDA Approves Inqovi for Acute Myeloid Leukemia

  FRIDAY, May 22, 2026 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of a···【Read More】

  Update: 25 May,2026Source: BigbearViews: 128

• FDA Approves Ocrevus (ocrelizumab) for Pediatric Patients 10 Years of Age and Older with Relapsing-Remitting Multiple Sclerosis

  Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) intrave···【Read More】

  Update: 21 May,2026Source: BigbearViews: 112

• FDA Approves Baxfendy (baxdrostat) as the First Aldosterone Synthase Inhibitor Treatment for Adults with Hypertension

  May 18, 2026 – Baxfendy (baxdrostat) from AstraZeneca has received FDA approval as the world's first aldosterone synthase inhibitor (ASI) for use ···【Read More】

  Update: 20 May,2026Source: BigbearViews: 127

• EU Recommends Expanding New Indications for Nivolumab (Opdivo)

  Recently, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending chan···【Read More】

  Update: 19 May,2026Source: BigbearViews: 105

• FDA Approves Immgolis (golimumab-sldi) and Immgolis Intri (golimumab-sldi) as the First Interchangeable Biosimilars to Simponi and Simponi Aria

  May 15, 2026 — The FDA has approved Immgolis (golimumab-sldi) as an interchangeable biosimilar to Simponi (golimumab), and Immgolis Intri (golimumab-s···【Read More】

  Update: 18 May,2026Source: BigbearViews: 107

• EU Approves New Expanded Indications for Dabrafenib and Trametinib!

  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending amendmen···【Read More】

  Update: 11 May,2026Source: BigbearViews: 116